How Can Rotational Thromboelastometry as a Point-of-Care Method Be Useful for the Management of Secondary Thromboprophylaxis in High-Risk Pregnant Patients?
Lucia StanciakovaMiroslava DobrotovaPavol HollyJana ZolkovaLubica VadelovaIngrid SkornovaJela IvankovaTomas BolekMatej SamošMarian GrendarJan DankoPeter KubiszJan StaskoPublished in: Diagnostics (Basel, Switzerland) (2021)
Thromboprophylaxis with low-molecular-weight heparin (LMWH) for patients with a history of venous thromboembolism (VTE) is suggested. Rotational thromboelastometry (ROTEM®) represents an innovative point-of-care method enabling the complex and quick evaluation of hemostasis. However, there are only episodic cases of its use for hemostasis assessment and guidance of LMWH in pregnancy. Therefore, we provide the results of unique prospective and longitudinal monitoring of hemostasis in high-risk pregnant women, which we used for the individualized optimalization of secondary thromboprophylaxis. According to the shortening of clot formation time (CFT) in EXTEM (p = 0.0007 from the 26th gestational week vs. controls) and INTEM (p = 0.002 from the 35th gestational week), increase in alpha angle (AA) in EXTEM, INTEM, and HEPTEM, and the persistence of increase in maximum clot firmness (MCF) in EXTEM, INTEM, and HEPTEM (p < 0.001 from the 26th and 35th gestational week vs. controls for EXTEM and INTEM, p = 0.0012 from the 26th gestational week in HEPTEM), LMWH dose was modified. Even after the postpartum period, AA in EXTEM was steeper than in controls (p = 0.0007), indicating that hemostasis is not fully normalized after 6-8 weeks following delivery. Therefore, ROTEM may be a useful tool for the individual evaluation of the termination of anticoagulant thromboprophylaxis.
Keyphrases
- venous thromboembolism
- pregnant women
- weight gain
- direct oral anticoagulants
- pregnancy outcomes
- end stage renal disease
- birth weight
- body mass index
- newly diagnosed
- placebo controlled
- ejection fraction
- chronic kidney disease
- prognostic factors
- high resolution
- breast cancer cells
- randomized controlled trial
- atrial fibrillation
- gestational age
- cross sectional
- patient reported
- patient reported outcomes
- clinical trial
- study protocol
- double blind
- growth factor